EasySep™ Direct Human B Cell Isolation Kit
Immunomagnetic negative selection from whole blood kit
-
EasySep™ Direct Human B Cell Isolation Kit -
Label for EasySep™ Direct Human B Cell Isolation Kit
More Views
Required Products
-
Magnet for column-free immunomagnetic separation -
Dulbecco’s phosphate-buffered saline without calcium and magnesium -
Compatible antibodies for purity assessment of isolated cells
Overview
Isolate highly purified B cells directly from human whole blood without the need for density gradient centrifugation, RBC sedimentation or lysis. This platform provides fast and fully immunomagnetic negative selection.
This cell isolation kit targets non-B cells for removal with EasySep™ Direct RapidSpheres™ and antibodies recognizing specific surface antigens. Unwanted cells are separated from desired cells using an EasySep™ magnet, and untouched target cells are then pipetted or poured into a new tube.
Isolated cells can be used directly in downstream applications such as flow cytometry, culture or DNA/RNA extraction.
This cell isolation kit targets non-B cells for removal with EasySep™ Direct RapidSpheres™ and antibodies recognizing specific surface antigens. Unwanted cells are separated from desired cells using an EasySep™ magnet, and untouched target cells are then pipetted or poured into a new tube.
Isolated cells can be used directly in downstream applications such as flow cytometry, culture or DNA/RNA extraction.
Advantages:
• > 99.9% RBC depletion without the need for density gradient centrifugation, sedimentation, or lysis
• Up to 95% purity of isolated cells
• Fast, easy-to-use and column-free
• Isolated cells are untouched
• Up to 95% purity of isolated cells
• Fast, easy-to-use and column-free
• Isolated cells are untouched
Components:
- EasySep™ Direct Human B Cell Isolation Kit (Catalog #19674)
- EasySep™ Direct Human B Cell Isolation Cocktail, 2 x 2.5 mL
- EasySep™ Direct RapidSpheres™, 4 x 2.5 mL
- RoboSep™ Human B Cell Isolation Kit (Catalog #19674RF)
- EasySep™ Direct Human B Cell Isolation Cocktail, 2 x 2.5 mL
- EasySep™ Direct RapidSpheres™, 4 x 2.5 mL
- RoboSep™ Buffer (Catalog #20104)
- RoboSep™ Filter Tips (Catalog #20125) x 2
Magnet Compatibility:
• EasySep™ Magnet (Catalog #18000)
• “The Big Easy” EasySep™ Magnet (Catalog #18001)
• Easy 50 EasySep™ Magnet (Catalog #18002)
• EasyEights™ EasySep™ Magnet (Catalog #18103)
• RoboSep™-S (Catalog #21000)
Subtype:
Cell Isolation Kits
Cell Type:
B Cells
Species:
Human
Sample Source:
Whole Blood
Selection Method:
Negative
Application:
Cell Isolation
Brand:
EasySep; RoboSep
Area of Interest:
Immunology
Related Products
-
Primary human cells, fresh -
EasySep™ Human B Cell Isolation Kit
9-Minute cell isolation kit using immunomagnetic negative selection
Labeling Antibodies
-
Anti-Human CD19 Antibody, Clone HIB19
Mouse monoclonal IgG1 antibody against human, chimpanzee CD19 -
Anti-Human CD20 Antibody, Clone 2H7
Mouse monoclonal IgG2b antibody against human, rhesus, cynomolgus CD20
Scientific Resources
Product Documentation
Document Type
Product Name
Catalog #
Lot #
Language
Educational Materials
(14)
Load More Educational Materials
Frequently Asked Questions
Can EasySep™ be used for either positive or negative selection?
Yes. The EasySep™ kits use either a negative selection approach by targeting and removing unwanted cells or a positive selection approach targeting desired cells. Depletion kits are also available for the removal of cells with a specific undesired marker (e.g. GlyA).
How does the separation work?
Magnetic particles are crosslinked to cells using Tetrameric Antibody Complexes (TAC). When placed in the EasySep™ Magnet, labeled cells migrate to the wall of the tube. The unlabeled cells are then poured off into a separate fraction.
Which columns do I use?
The EasySep™ procedure is column-free. That's right - no columns!
How can I analyze the purity of my enriched sample?
The Product Information Sheet provided with each EasySep™ kit contains detailed staining information.
Can EasySep™ separations be automated?
Yes. RoboSep™, the fully automated cell separator, automates all EasySep™ labeling and cell separation steps.
Can EasySep™ be used to isolate rare cells?
Yes. We recommend a cell concentration of 2x108 cells/mL and a minimum working volume of 100 µL. Samples containing 2x107 cells or fewer should be suspended in 100 µL of buffer.
Are the EasySep™ magnetic particles FACS-compatible?
Yes, the EasySep™ particles are flow cytometry-compatible, as they are very uniform in size and about 5000X smaller than other commercially available magnetic beads used with column-free systems.
Can the EasySep™ magnetic particles be removed after enrichment?
No, but due to the small size of these particles, they will not interfere with downstream applications.
Can I alter the separation time in the magnet?
Yes; however, this may impact the kit's performance. The provided EasySep™ protocols have already been optimized to balance purity, recovery and time spent on the isolation.
For positive selection, can I perform more than 3 separations to increase purity?
Yes, the purity of targeted cells will increase with additional rounds of separations; however, cell recovery will decrease.
How does the binding of the EasySep™ magnetic particle affect the cells? is the function of positively selected cells altered by the bound particles?
Hundreds of publications have used cells selected with EasySep™ positive selection kits for functional studies. Our in-house experiments also confirm that selected cells are not functionally altered by the EasySep™ magnetic particles.
If particle binding is a key concern, we offer two options for negative selection. The EasySep™ negative selection kits can isolate untouched cells with comparable purities, while RosetteSep™ can isolate untouched cells directly from whole blood without using particles or magnets.
If particle binding is a key concern, we offer two options for negative selection. The EasySep™ negative selection kits can isolate untouched cells with comparable purities, while RosetteSep™ can isolate untouched cells directly from whole blood without using particles or magnets.
Read More
Product Applications
This product is designed for use in the following research area(s) as part of the highlighted workflow stage(s). Explore these workflows to learn more about the other products we offer to support each research area.
Research Area
Workflow Stages for
Workflow Stages
Data and Publications
Data
Figure 1. Typical EasySep™ Direct Human B Cell Isolation Profile
Starting with human whole blood from normal healthy donors, the typical B cell (CD3-CD19+) content of the non-lysed final isolated fraction is 95.3 ± 2.7% (gated on CD45) or 88.5 ± 11.5% (not gated on CD45). In the above example, the B cell (CD3-CD19+) content of the lysed whole blood start sample and the non-lysed final isolated fraction is 6.2% and 95.9% (gated on CD45), respectively, or 6.2% and 95.8% (not gated on CD45), respectively. The starting frequency of B cells in the non-lysed whole blood start sample above is 0.011% (data not shown).
Publications
(2)
mAbs 2016 JUL
A novel antibody discovery platform identifies anti-influenza A broadly neutralizing antibodies from human memory B cells.
Abstract
Abstract
Monoclonal antibody isolation directly from circulating human B cells is a powerful tool to delineate humoral responses to pathological conditions and discover antibody therapeutics. We have developed a platform aimed at improving the efficiencies of B cell selection and V gene recovery. Here, memory B cells are activated and amplified using Epstein-Barr virus infection, co-cultured with CHO-muCD40L cells, and then assessed by functional screenings. An in vitro transcription and translation (IVTT) approach was used to analyze variable (V) genes recovered from each B cell sample and identify the relevant heavy/light chain pair(s). We achieved efficient amplification and activation of memory B cells, and eliminated the need to: 1) seed B cells at clonal level (≤1 cell/well) or perform limited dilution cloning; 2) immortalize B cells; or 3) assemble V genes into an IgG expression vector to confirm the relevant heavy/light chain pairing. Cross-reactive antibodies targeting a conserved epitope on influenza A hemagglutinin were successfully isolated from a healthy donor. In-depth analysis of the isolated antibodies suggested their potential uses as anti-influenza A antibody therapeutics and uncovered a distinct affinity maturation pathway. Importantly, our results showed that cognate heavy/light chain pairings contributed to both the expression level and binding abilities of our newly isolated VH1-69 family, influenza A neutralizing antibodies, contrasting with previous observations that light chains do not significantly contribute to the function of this group of antibodies. Our results further suggest the potential use of the IVTT as a powerful antibody developability assessment tool.
Journal of immunology (Baltimore, Md. : 1950) 2016 JUL
FcγRIIB-Independent Mechanisms Controlling Membrane Localization of the Inhibitory Phosphatase SHIP in Human B Cells.
Abstract
Abstract
SHIP is an important regulator of immune cell signaling that functions to dephosphorylate the phosphoinositide phosphatidylinositol 3,4,5-trisphosphate at the plasma membrane and mediate protein-protein interactions. One established paradigm for SHIP activation involves its recruitment to the phospho-ITIM motif of the inhibitory receptor FcγRIIB. Although SHIP is essential for the inhibitory function of FcγRIIB, it also has critical modulating functions in signaling initiated from activating immunoreceptors such as B cell Ag receptor. In this study, we found that SHIP is indistinguishably recruited to the plasma membrane after BCR stimulation with or without FcγRIIB coligation in human cell lines and primary cells. Interestingly, fluorescence recovery after photobleaching analysis reveals differential mobility of SHIP-enhanced GFP depending on the mode of stimulation, suggesting that although BCR and FcγRIIB can both recruit SHIP, this occurs via distinct molecular complexes. Mutagenesis of a SHIP-enhanced GFP fusion protein reveals that the SHIP-Src homology 2 domain is essential in both cases whereas the C terminus is required for recruitment via BCR stimulation, but is less important with FcγRIIB coligation. Experiments with pharmacological inhibitors reveal that Syk activity is required for optimal stimulation-induced membrane localization of SHIP, whereas neither PI3K or Src kinase activity is essential. BCR-induced association of SHIP with binding partner Shc1 is dependent on Syk, as is tyrosine phosphorylation of both partners. Our results indicate that FcγRIIB is not uniquely able to promote membrane recruitment of SHIP, but rather modulates its function via formation of distinct signaling complexes. Membrane recruitment of SHIP via Syk-dependent mechanisms may be an important factor modulating immunoreceptor signaling.
PRODUCTS ARE FOR RESEARCH USE ONLY AND NOT INTENDED FOR HUMAN OR ANIMAL DIAGNOSTIC OR THERAPEUTIC USES UNLESS OTHERWISE STATED. FOR ADDITIONAL INFORMATION ON QUALITY AT STEMCELL, REFER TO WWW.STEMCELL.COM/COMPLIANCE.